Literature DB >> 19506285

Interaction between clopidogrel and proton pump inhibitors.

Mark H Friesen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19506285      PMCID： PMC2691441          DOI： 10.1503/cmaj.1090014

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  8 in total

1.  Mass balance study of [14C] rabeprazole following oral administration in healthy subjects.

Authors:  T Setoyama; W J Drijfhout; N C van de Merbel; T J Humphries; J Hasegawa
Journal:  Int J Clin Pharmacol Ther       Date:  2006-11       Impact factor: 1.366

2.  Users' guides to the medical literature. IV. How to use an article about harm. Evidence-Based Medicine Working Group.

Authors:  M Levine; S Walter; H Lee; T Haines; A Holbrook; V Moyer
Journal:  JAMA       Date:  1994-05-25       Impact factor: 56.272

3.  A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.

Authors:  David N Juurlink; Tara Gomes; Dennis T Ko; Paul E Szmitko; Peter C Austin; Jack V Tu; David A Henry; Alex Kopp; Muhammad M Mamdani
Journal:  CMAJ       Date:  2009-01-28       Impact factor: 8.262

4.  Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation.

Authors:  T Ishizaki; K Chiba; K Manabe; E Koyama; M Hayashi; S Yasuda; Y Horai; Y Tomono; C Yamato; T Toyoki
Journal:  Clin Pharmacol Ther       Date:  1995-08       Impact factor: 6.875

5.  Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.

Authors:  Xue-Qing Li; Tommy B Andersson; Marie Ahlström; Lars Weidolf
Journal:  Drug Metab Dispos       Date:  2004-08       Impact factor: 3.922

6.  Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.

Authors:  Martine Gilard; Bertrand Arnaud; Jean-Christophe Cornily; Grégoire Le Gal; Karine Lacut; Geneviève Le Calvez; Jacques Mansourati; Dominique Mottier; Jean-François Abgrall; Jacques Boschat
Journal:  J Am Coll Cardiol       Date:  2008-01-22       Impact factor: 24.094

7.  Genetic determinants of response to clopidogrel and cardiovascular events.

Authors:  Tabassome Simon; Céline Verstuyft; Murielle Mary-Krause; Lina Quteineh; Elodie Drouet; Nicolas Méneveau; P Gabriel Steg; Jean Ferrières; Nicolas Danchin; Laurent Becquemont
Journal:  N Engl J Med       Date:  2008-12-22       Impact factor: 91.245

8.  Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.

Authors:  David S Small; Nagy A Farid; Christopher D Payne; Govinda J Weerakkody; Ying G Li; John T Brandt; Daniel E Salazar; Kenneth J Winters
Journal:  J Clin Pharmacol       Date:  2008-02-26       Impact factor: 3.126
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.